LYNX1 CAPITAL MANAGEMENT LP purchased 2.5% of their position (131.80K shares) of TSCAN THERAPEUTICS, INC. on the open market
Open‑market purchase worth $385.8K — a small addition. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 12/16/2024ACC: 0000902664-24-006934
10% Owner
Since May 2023
+131.80K
Net shares
Net buyer
$385.8K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
131.80K acquired
Non-Derivative Transactions2
Common stock, $0.0001 par value per share ("Common Stock")
Indirect
Shares
+31.80K
Price / share
$3.01
Trade value
$95.63K
% of position
0.6%
12/12/2024
5.23M→5.26M
Common Stock
Indirect
Shares
+100K
Price / share
$2.90
Trade value
$290.14K
% of position
1.9%
12/13/2024
5.26M→5.36M
Total
Net shares
+131.80K
Net value
$385.77K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.0001 par value per share ("Common Stock") Indirect | 12/12/2024 | P · Purchase | +31.80K | $3.01 | $95.63K | 0.6% | 5.23M | 5.26M |
| Common Stock Indirect | 12/13/2024 | P · Purchase | +100K | $2.90 | $290.14K | 1.9% | 5.26M | 5.36M |
| Total | +131.80K | $385.77K | ||||||
Derivative Transactions0
No derivative transactions reported